View Older Stories View More Recent Stories

Feb 15, 2022 05:46AM Social Capital Suvretta Holdings (PRTC) Files Form S-4 for Proposed Merger with Akili Interactive
Feb 15, 2022 02:00AM PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I
Feb 10, 2022 07:00AM PureTech to Present at the SVB Leerink 11th Annual Global Healthcare Conference
Jan 31, 2022 06:50AM PureTech Founded Entity Gelesis to Launch Plenity® National Media Campaign That Challenges Restrictive Dieting Norms
Jan 26, 2022 07:02AM PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
Jan 14, 2022 02:00AM PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar
Jan 7, 2022 07:00AM PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference
Jan 6, 2022 02:00AM PureTech’s LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone
Jan 5, 2022 07:05AM PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee
Dec 16, 2021 05:57AM PureTech Health Plc (PRTC) Issues End of Year Report on Key Progress Across Wholly Owned Programs and Founded Entities
Dec 16, 2021 02:00AM PureTech Provides End of Year Report on Key Progress Across Wholly Owned Programs and Founded Entities
Dec 8, 2021 07:00AM PureTech Health Plc (PRTC) Reports Preclinical Proof-of-Concept Data for LYT-300
Dec 8, 2021 07:00AM PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions
Dec 7, 2021 07:07AM PureTech Health Plc (PRTC) Advances LYT-300 nto Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions
Dec 7, 2021 07:00AM PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions
Dec 1, 2021 07:10AM PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Off
Nov 18, 2021 07:12AM PureTech's (PRTC) Gelesis (CPSR) Announces $30M Plenity Order from Ro
Nov 18, 2021 07:10AM PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro
Nov 16, 2021 07:06AM PureTech Health Plc (PRTC) Announces Publication of Phase 1 Results for LYT-100
Nov 16, 2021 07:00AM PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates
Nov 15, 2021 07:00AM PureTech Announces Participation in Two Upcoming Investor Conferences
Nov 12, 2021 07:00AM PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Nov 11, 2021 07:03AM PureTech Health (PRTC) Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer
Nov 11, 2021 07:00AM PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer
Nov 9, 2021 07:37AM PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
Nov 9, 2021 02:00AM PureTech Announces Participation at the Jefferies London Healthcare Conference
Nov 1, 2021 06:22AM PureTech Health (PRTC) Notes Publication in Nature’s Scientific Reports Featuring Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
Nov 1, 2021 06:20AM PureTech Is Pleased to Note Publication in Nature’s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
Oct 14, 2021 07:01AM PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
Oct 5, 2021 08:01AM PureTech Health (PRTC) Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Oct 5, 2021 08:01AM PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Oct 5, 2021 08:00AM PureTech Founded Entity Sonde Health Launches Vocal Biomarker Technology to Monitor Mental Health and Well-Being
Sep 29, 2021 08:02AM PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan
Sep 20, 2021 11:04AM PureTech (PRTC) Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as Potential Cause of and Therapeutic Target for Obesity and Insulin
Sep 20, 2021 11:04AM PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resi
Sep 14, 2021 07:00AM PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Sep 10, 2021 06:00AM PureTech Health Plc's (PRTC) Vor Biopharma (VOR) Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
Sep 10, 2021 02:00AM PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia
Aug 24, 2021 02:00AM PureTech Health plc – Half-Year Report
Aug 23, 2021 07:00AM PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021
Aug 17, 2021 08:05AM PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments
Aug 13, 2021 07:00AM PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer
Aug 11, 2021 07:00AM PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503/IMB-150 for Interstitial Cystitis/Bladder Pain Syndrome
Aug 3, 2021 02:00AM PureTech: Notice of Half-Yearly Results
Jul 22, 2021 08:09AM PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children With ADHD
Jul 21, 2021 07:03AM PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing
Jul 19, 2021 07:02AM PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
Jul 9, 2021 07:00AM PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leuk
Jul 8, 2021 09:05AM PureTech Founded Entity Sonde Health Announces Collaboration with Qualcomm Technologies for Use of Vocal Biomarker Technology on Qualcomm Snapdragon Mobile Platforms
Jul 7, 2021 07:07AM PureTech (PRTC) Announces Clinical Trial and Supply Agreement with BeiGene (BGNE) to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
View More Recent Stories View Older Stories